Search company, investor...

ISTO Technologies

istotech.com

Founded Year

1997

Stage

Merger | Merged

Total Raised

$38.56M

About ISTO Technologies

ISTO Technologies is a regenerative medicine company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. The company was founded in 1997 and is based in St. Louis, Missouri.

Headquarters Location

1155 Olivette Executive Parkway Suite 200

St. Louis, Missouri, 63132,

United States

314-995-6049

Missing: ISTO Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ISTO Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ISTO Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ISTO Technologies is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ISTO Technologies Patents

ISTO Technologies has filed 1 patent.

The 3 most popular patent topics include:

  • Developmental genes and proteins
  • Dosage forms
  • Drug delivery devices
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/14/2019

11/30/2021

Transcription factors, Skeletal system, Orthopedic surgical procedures, Stem cells, Developmental genes and proteins

Grant

Application Date

3/14/2019

Grant Date

11/30/2021

Title

Related Topics

Transcription factors, Skeletal system, Orthopedic surgical procedures, Stem cells, Developmental genes and proteins

Status

Grant

Latest ISTO Technologies News

Smisson-Cartledge Biomedical Names John E. Hart as President, CEO

Sep 15, 2021

Smisson-Cartledge Biomedical Names John E. Hart as President, CEO Smisson-Cartledge Biomedical Names John E. Hart as President, CEO New leader has more than 35 years of executive leadership experience in the medical device, life science and biologics fields. Business Wire09.15.21 Smisson-Cartledge Biomedical LLC , an ISO 13485:2016 certified manufacturer of the ThermaCor 1200 Rapid Infuser technology for use in a broad spectrum of medical procedures, has named John E Hart as president and CEO. Hart has more than 35 years of executive leadership experience in the medical device, life science and biologics fields serving in general management, marketing, sales, business development and operational management roles. Most recently, Hart served as a member of the turnaround team at Conmed Corporation, where he led the Cardiology and Critical Care Division to double digit revenue and profit growth. He also led the Healthcare Solutions team, which was responsible for corporate, national and government accounts. Prior to that he served as chief operating officer for ISTO Technologies Inc. for three years and president and CEO of Vidar Systems Corporation for five years. Both companies achieved successful exits. “John is the right leader for Smisson-Cartledge Biomedical,” said Hugh F. Smisson, III M.D., SCB’s board chairman. “John’s extensive background in management, sales, marketing and business development should help strengthen our partnerships, develop strategic alliances, expand our sales presence and grow our profitability in the trauma, transplant and critical care markets."   Hart has also held senior executive positions in Fortune 500 companies, including Stryker Orthopaedics (Stryker Corporation) and U.S. Surgical (Covidien – now Medtronic plc). Hart earned a bachelor of science degree from The College of New Jersey and an MBA from Southern New Hampshire University. He is a member of the Board of Directors for Virginia Bio. “I am very excited to be joining the Smisson-Cartledge Biomedical team,” said Hart. “I believe that SCB’s critical product line and talented team will be key factors in leading the company’s next chapter for success and growth with the ThermaCor 1200 which is an innovative product to help save patient lives.”   SCB is a medical device company focused on delivering clinically superior and economically beneficial therapeutic solutions for the treatment of thermal infusion care. The ThermaCor 1200 Rapid Infusion Pump provides temperature-controlled fluid therapies. SCB has developed and patented a highly efficient heat transfer process that can heat or cool fluids at a wide range of flow rates through a portable pump and single-use disposable cassettes. SCB has also developed and patented a compact in-line air trap/purging system. Related Breaking News Business Wire 09.15.21 Business Wire 09.15.21 Globe Newswire 09.15.21 Business Wire 09.15.21 Business Wire 09.15.21 Siemens Healthineers 09.14.21 Business Wire 09.14.21 PR Newswire 09.14.21 09.14.21 Business Wire 09.13.21 Business Wire 09.13.21 RapidAI 09.13.21 PR Newswire 09.13.21 Business Wire 09.13.21 Business Wire 09.13.21

ISTO Technologies Frequently Asked Questions (FAQ)

  • When was ISTO Technologies founded?

    ISTO Technologies was founded in 1997.

  • Where is ISTO Technologies's headquarters?

    ISTO Technologies's headquarters is located at 1155 Olivette Executive Parkway, St. Louis.

  • What is ISTO Technologies's latest funding round?

    ISTO Technologies's latest funding round is Merger.

  • How much did ISTO Technologies raise?

    ISTO Technologies raised a total of $38.56M.

  • Who are the investors of ISTO Technologies?

    Investors of ISTO Technologies include Isto Biologics, Thompson Street Capital Partners, Mid-America Transplant Services, Alafi Capital, Ascension Ventures and 5 more.

  • Who are ISTO Technologies's competitors?

    Competitors of ISTO Technologies include c-LEcta, Bone Biologics, Alucent Biomedical, RhinoCyte, Cebix and 12 more.

Compare ISTO Technologies to Competitors

C
Cellular Engineering Technologies

Cellular Engineering Technologies is a biotechnology tissue engineering company.

B
BioRegenix

BioRegenix is a biotechnology company committed to the development of tissue regeneration technology.

I
InCytu

InCytu is an applied biotechnology company developing cell therapy delivery devices which promote targeted tissue healing/regeneration or modulate the immune system. Per the company, InCytu is able to harness and amplify the body's natural regenerative processes using Cellarium's platform technology. The InCytu technology was first developed in Professor David Mooney's lab at Harvard University. Cellarium's pre-programmed polymer system aims to locally deliver physiologically correct cells and factors so that the cells integrate naturally into damaged or deficient tissues.

A
Aderans Research Institute

ARI is developing biotechnology solutions to the pervasive problem of hair loss. This cell therapy and tissue engineering research focuses on developing hair follicle progenator tissue for cosmetic hair replacement surgery. Safe and effective tissue engineered products will be developed based upon the molecular and cellular mechanisms of hair growth and multiplicati. ARI was created by Aderans Co., of Tokyo, Japan and its US Susidiary Bosley, the World's largest hair restoration practice.The company was formerly known as BioAmide .

R
RhinoCyte

RhinoCyte is a biotechnology company that has developed a method of isolating adult stem cells located in the olfactory regions of the mucosal lining of the human nasal passageway, which can be used in therapies for spinal cord injury, multiple sclerosis, ALS and Parkinson's Disease.

Harihar Biotech Logo
Harihar Biotech

Harihar Biotech is a North India based biotechnology company and is a part of HH Bio group, with special focus on Plant Tissue Culture.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.